Drugs / AVID100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03094169 | Feb 2017 → Nov 2020 | head and neck squamous cell carcinoma, non-small cell lung carcinoma, triple-negative breast carcinoma | Formation Biologics | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVID100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03094169 ↗ |
| Route | Intravenous | “study drug administered by 2-hour IV infusion” NCT03094169 ↗ |